Cell and Gene Therapy Is Forcing a Rethink of Where Medicines Are Made

For decades, the geography of drug manufacturing was relatively straightforward. Large, centralized facilities produced therapies at scale, often far removed from the patients they ultimately served. The system was designed for efficiency, standardization, and long production runs. It worked because the products it supported were stable, predictable, and broadly distributed.

Cell and gene therapies do not fit as neatly into that model.

These treatments are often derived from a patient’s own cells, engineered outside the body, and then returned to the same patient within a narrow clinical window. In some cases, the viability of the therapy is measured not in weeks or months of shelf life, but in hours or days. That fundamental difference is quietly reshaping one of the most established assumptions in life sciences manufacturing: that production should be centralized.

What is emerging instead is a gradual but meaningful shift toward decentralized manufacturing, where production is distributed across multiple smaller, highly controlled environments that are closer to the point of care.

This shift is not simply about convenience or logistics. It is being driven by biology, time sensitivity, and the increasing complexity of advanced therapies that depend on tightly controlled handling from start to finish.

In practice, this means manufacturing is beginning to move into spaces that look very different from traditional pharmaceutical campuses. Rather than a single large facility serving global demand, organizations are exploring networks of smaller GMP-compliant sites that can support regional or even hospital-adjacent production. In some cases, manufacturing steps are being integrated directly into clinical environments, particularly in oncology centers where cell therapies are administered.

The goal is not to eliminate centralized manufacturing entirely, but to supplement it with a more distributed model that reduces transport risk, shortens turnaround times, and increases resilience in clinical supply chains.

This shift is particularly visible in cell and gene therapy programs where chain-of-identity and chain-of-custody are as critical as the manufacturing process itself. When a patient’s own cells are being manipulated and returned, any delay or deviation introduces not only logistical challenges but clinical risk. Every hour between collection and re-infusion matters, and that urgency has made proximity an operational requirement rather than a preference.

As organizations begin to design around this reality, the infrastructure supporting these therapies is evolving as well. Cleanroom environments, once designed as large, fixed, long-term installations, are increasingly being reconsidered through the lens of flexibility and speed. Instead of building single-purpose facilities that take years to design and validate, companies are exploring modular and adaptable environments that can be deployed more quickly and reconfigured as therapies mature.

Modular cleanrooms are not emerging as a replacement for traditional facilities, but as a response to a specific set of constraints. The need for faster deployment is one of the most immediate pressures. Cell and gene therapy programs often move from clinical trial to expansion faster than conventional construction timelines can accommodate. At the same time, manufacturing processes themselves are still evolving, meaning facility requirements can change mid-development. A static facility risks becoming misaligned with the process it was designed to support.

This has led to a growing emphasis on cleanroom environments that can scale incrementally, allowing organizations to expand capacity without fully rebuilding infrastructure. It also supports a more experimental phase of manufacturing, where layouts, workflows, and environmental classifications may need to be adjusted as processes are validated.

The implications extend beyond construction timelines. As manufacturing becomes more distributed, maintaining consistency across sites becomes increasingly important. Each cleanroom, whether located within a hospital, a regional hub, or a standalone facility, must meet the same regulatory standards and support reproducible outcomes. This creates pressure for more standardized design approaches and repeatable infrastructure models that can be replicated across locations without introducing variability.

At the same time, the regulatory environment is adapting to this new reality. Agencies are increasingly focused on ensuring that distributed manufacturing networks maintain the same level of control, traceability, and data integrity as centralized facilities. This reinforces the importance of environmental monitoring, digital documentation, and tightly controlled workflows within each cleanroom environment.

Within this broader shift, organizations like CleanSpace are working alongside therapy developers, healthcare systems, and life sciences companies to support the implementation of modular cleanroom environments that align with GMP requirements while allowing for greater flexibility in how and where manufacturing capacity is deployed. The emphasis is less on the physical structure itself and more on enabling a manufacturing model that can adapt to the pace of therapeutic innovation.

What is emerging is a different way of thinking about infrastructure altogether. Cleanrooms are no longer just fixed assets built to support a single production strategy. Increasingly, they are becoming adaptable nodes within a larger manufacturing network, capable of shifting as therapies evolve and patient needs change.

As cell and gene therapies continue to move from experimental treatments into broader clinical use, the demand for distributed manufacturing capacity is likely to increase. The challenge will not only be producing these therapies at scale, but ensuring that the environments in which they are made can keep pace with the speed and complexity of the science itself.

In that sense, the evolution of cleanroom design is not separate from the evolution of the therapies it supports. It is part of the same transformation—one that is redefining not just how medicines are made, but where, and how quickly they can reach the patients who depend on them.